Disease-modifying therapies in Alzheimer's, as of Q2 2026
The current treatment landscape is narrow, the access constraints are operational, and the next material change is delivery format — not a new mechanism.
Two anti-amyloid antibodies have traditional FDA approval; subcutaneous formulations are advancing; the post-amyloid pipeline is portfolio-shaped.
Alzheimer's diagnostic pathways, as of Q2 2026
The diagnostic toolkit is broader than it was three years ago, but the post-diagnostic system has not scaled at the same pace.
Plasma biomarkers are entering routine workflows alongside established CSF and PET options, with confirmatory imaging still standard before disease-modifying therapy.
Alzheimer's regulatory and reimbursement landscape, as of Q2 2026
Regulatory clarity has improved; reimbursement clarity is still evolving; international access still varies meaningfully across major markets.
Two anti-amyloid antibodies have traditional FDA approval; CMS coverage operates under a coverage-with-evidence-development framework; international approvals diverge.